Art. 105 Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 3×

The management of funds intended for activities connected with pharmacovigilance, the operation of communication networks and market surveillance shall be under the permanent control of the national competent authorities in order to guarantee their independence in the performance of those pharmacovigilance activities.

The first paragraph shall not preclude the national competent authorities from charging fees to marketing authorisation holders for performing those activities by the national competent authorities on the condition that their independence in the performance of those pharmacovigilance activities is strictly guaranteed.

  • Directive (EU) 2004/27Lawamends

  • Judgment of the Court (Third Chamber) of 25 November 2021. Delfarma Sp. z o.o. v Prezes Urzędu Rejestracji Produktów Leczniczych, Wyrobów MeDecision

    Title IX of Directive 2001/83, entitled ‘Pharmacovigilance’, comprises Articles 101 to 108 thereof.

    25 Nov 2021 · 62020CJ0488

  • Opinion of Mr Advocate General Geelhoed delivered on 21 October 2004. Commission of the European Communities v French Republic.Decision

    … Odvolávám se na článek 105 směrnice 2001/83. V tomto ohledu není nutné zkoumat, jakým způsobem je tato povinnost žadatele používána v praxi. Stejně tak jako lhůta pro vydání rozhodnutí: francouzská právní úprava …

    21 Oct 2004 · 62003CC0212